Skip to main content
. 2023 Nov 22;6(4):805–827. doi: 10.20517/cdr.2023.77

Figure 11.

Figure 11

(A) Schematic illustration of the preparation and mechanism of CB[7]-based nanomedicine (PG-Pt-LA/CB[7]) in overcoming drug resistance of CRC cells; (B) Changes of F. nucleatum levels in CRC cells with different treatments; (C) Changes of tumor volume in tumor-bearing mice with different formulations (**P < 0.01, ***P < 0.001). This figure is quoted with permission from Yan et al.[144]. CRC: Colorectal cancer.